Biodesix Inc
NASDAQ:BDSX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.19
2.12
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BDSX stock under the Base Case scenario is 1.93 USD. Compared to the current market price of 1.28 USD, Biodesix Inc is Undervalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biodesix Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BDSX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Biodesix Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biodesix Inc
Balance Sheet Decomposition
Biodesix Inc
Current Assets | 44m |
Cash & Short-Term Investments | 31.4m |
Receivables | 8m |
Other Current Assets | 4.6m |
Non-Current Assets | 58.7m |
PP&E | 30.6m |
Intangibles | 21.5m |
Other Non-Current Assets | 6.7m |
Current Liabilities | 13m |
Accounts Payable | 2.5m |
Accrued Liabilities | 6.5m |
Other Current Liabilities | 3.9m |
Non-Current Liabilities | 61.9m |
Long-Term Debt | 36.1m |
Other Non-Current Liabilities | 25.8m |
Earnings Waterfall
Biodesix Inc
Revenue
|
65.6m
USD
|
Cost of Revenue
|
-14.6m
USD
|
Gross Profit
|
51m
USD
|
Operating Expenses
|
-85.5m
USD
|
Operating Income
|
-34.6m
USD
|
Other Expenses
|
-9.3m
USD
|
Net Income
|
-43.8m
USD
|
Free Cash Flow Analysis
Biodesix Inc
USD | |
Free Cash Flow | USD |
BDSX Profitability Score
Profitability Due Diligence
Biodesix Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Biodesix Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
BDSX Solvency Score
Solvency Due Diligence
Biodesix Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Biodesix Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDSX Price Targets Summary
Biodesix Inc
According to Wall Street analysts, the average 1-year price target for BDSX is 3.16 USD with a low forecast of 3.03 USD and a high forecast of 3.68 USD.
Dividends
Current shareholder yield for BDSX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BDSX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
Contact
IPO
Employees
Officers
The intrinsic value of one BDSX stock under the Base Case scenario is 1.93 USD.
Compared to the current market price of 1.28 USD, Biodesix Inc is Undervalued by 34%.